AQP4 and neuromyelitis optica: We analyzed a cohort of NMO patients (a total of 60, 4 male and 56 female) that we recently established, recruiting individuals with new-onset, AQP4-IgG–seropositive NMO during acute attacks who had not received steroids or immunomodulatory therapy, along with age-matched control subjects (Table 1).